MS is a chronic disease of the CNS, well recognized for its diverse clinical presentations and outcomes. Clinicians continue to struggle to predict short- or long-term prognosis of persons affected by MS, to predict response to the growing array of disease-modifying treatments available, and to identify persons at risk of serious adverse events from those treatments. As such, valid, reliable, and objectively assessed biologic measures, that is, biomarkers, which can aid clinicians in predicting these outcomes, are sorely needed.^[@R1]^

Neurofilaments are key components of the neuronal cytoskeleton. They provide structural support to axons, and elevated levels of these proteins have been observed in several neurodegenerative diseases including MS. Chitinases are glycosyl hydrolases; chitinase 3-like 1 (CHI3L1) lacks chitinolytic activity and is expressed by microglia, macrophages, and astrocytes.^[@R2]^ In CIS, higher CSF levels of CHI3L1 are associated with shorter time to diagnosis of MS.^[@R2]^ Elevated CSF levels of neurofilament light chain (NF-L) have been associated with brain atrophy,^[@R3]^ and a recent longitudinal study of 41 persons with clinically isolated syndrome (CIS) or relapsing-remitting MS (RRMS) found that NF-L levels in CSF correctly classified 85% of participants with respect to disease activity over 2 years.^[@R4]^

In this issue of *Neurology® Neuroimmunology & Neuroinflammation*, Varhaug et al.^[@R5]^ sought to determine whether serum NF-L and CHI3L1 predict disease activity in RRMS. The study population included 85 participants in a randomized, double-blind controlled trial in which they were randomized to supplement with omega-3 fatty acids or placebo conducted over 6 months, with the addition of interferon-beta-1a subcutaneously 3 times weekly for the subsequent 18 months. Serum samples were drawn at baseline and months 3, 6, 12, and 24. Using these samples, the authors measured CHI3L1 concentrations using an ELISA and NF-L concentrations using a single-molecule array assay. They found that CHI3L1 levels were not associated with relapses, disability, or MRI measures of disease activity. By contrast, NF-L levels were associated with MRI measures. After accounting for age at enrollment, sex, and follow-up time, median (interquartile range) NF-L levels were higher in participants with new gadolinium-enhancing lesions (37.4 \[25.9--52.4\] pg/mL) than among those without such lesions (28.0 \[21.9--36.4\] pg/mL, *p* \< 0.001) and higher among participants with new T2 lesions (37.3 \[25.1--48.5\] pg/mL) than among those without new T2 lesions (27.7 \[21.8--35.1\] pg/mL, *p* \< 0.001). Despite the association of NF-L levels with MRI measures of disease activity, NF-L levels were not associated with relapses or disability progression. NF-L levels dropped after the initiation of interferon-beta-1a therapy, but the association of NF-L levels with MRI measures did not differ before or after the initiation of therapy. The observed decline in serum NF-L levels after the introduction of interferon-beta-1a therapy is consistent with observations in other cohorts that CSF NF-L levels declined after the introduction of natalizumab and fingolimod.^[@R6],[@R7]^ Within individuals, a 10-pg/mL increase in NF-L levels was associated with 48% increased odds of new gadolinium-enhancing lesions (OR, 1.48; 95% CI, 1.15--1.90) and 62% increased odds of a new T2 lesion (OR, 1.62; 95% CI, 1.22--2.15).

Strengths of the study include the prospective, longitudinal design, capture of clinically relevant outcomes including relapses and disability, and the use of mixed models, which allowed the identification of associations of NF-L levels with outcomes at the individual level. However, relevant limitations should be considered. All participants had RRMS; the average disease duration was short (1.0 years); and median disability was mild (Expanded Disability Status Scale score 2), and it is unknown whether these findings would generalize to individuals with longer disease duration or more severe disability. The study cohort was modest in size; only 23 (27.1%) participants experienced a relapse over the study period, and only 26 (30.5%) participants experienced disability progression, reducing the power to detect associations of serum NF-L levels with these outcomes. The magnitude of the effects observed was also small.

The authors suggest that serum NF-L may become a clinically useful biomarker for "detecting subclinical MRI activity and treatment response" in RRMS. Certainly, a serum NF-L measure is more practical for clinical purposes than a CSF measure. The ability to substitute a serum measure that could be assessed repeatedly for less frequent, less convenient, and more costly MRIs would be welcome. However, considerably more work is needed for serum NF-L levels to be appropriate for use in practice. We need to establish that the associations reported apply to other MS populations, which differ with respect to their demographic (age, sex, and race) and clinical (disability, disease duration, clinical course, and comorbidities) characteristics and that the magnitude and direction of these associations are consistent. We also need to determine whether a 10-pg/mL change in NF-L levels for an individual with MS reproducibly indicates subclinical disease activity with adequate sensitivity and specificity, and whether reductions in those levels indicate resolution of activity for that individual. The lack of association between NF-L levels and clinical disease activity also needs to be addressed, hopefully by the use of larger cohorts.

Serum NF-L levels deserve continued evaluation as a biomarker of disease activity. However, several large, prospective cohort studies with comprehensively characterized and heterogeneous participants followed over longer periods are needed to determine whether it should be adopted in clinical practice.
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